483 related articles for article (PubMed ID: 19887781)
1. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients.
Costa E; Swinkels DW; Laarakkers CM; Rocha-Pereira P; Rocha S; Reis F; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Acta Haematol; 2009; 122(4):226-9. PubMed ID: 19887781
[No Abstract] [Full Text] [Related]
2. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
3. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G
Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
[TBL] [Abstract][Full Text] [Related]
4. Increased hepcidin-25 and erythropoietin responsiveness in patients with cardio-renal anemia syndrome.
Kato A
Future Cardiol; 2010 Nov; 6(6):769-71. PubMed ID: 21142632
[TBL] [Abstract][Full Text] [Related]
5. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
6. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients.
van der Putten K; Jie KE; van den Broek D; Kraaijenhagen RJ; Laarakkers C; Swinkels DW; Braam B; Gaillard CA
Eur J Heart Fail; 2010 Sep; 12(9):943-50. PubMed ID: 20601671
[TBL] [Abstract][Full Text] [Related]
7. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.
Kato A; Tsuji T; Luo J; Sakao Y; Yasuda H; Hishida A
Am J Nephrol; 2008; 28(1):115-21. PubMed ID: 17943020
[TBL] [Abstract][Full Text] [Related]
8. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin.
Hohaus S; Massini G; Giachelia M; Vannata B; Bozzoli V; Cuccaro A; D'Alo' F; Larocca LM; Raymakers RA; Swinkels DW; Voso MT; Leone G
J Clin Oncol; 2010 May; 28(15):2538-43. PubMed ID: 20406921
[TBL] [Abstract][Full Text] [Related]
9. Hepcidin and iron deficiency in pre-kidney transplant patients.
Sancho A; Pastor MC; Troya M; Bonal J; Bayés B; Morales-Indiano C; Lauzurica R; Romero R
Transplant Proc; 2009; 41(6):2079-81. PubMed ID: 19715836
[TBL] [Abstract][Full Text] [Related]
10. Serum prohepcidin and hepcidin in hemodialyzed patients undergoing iron therapy.
Malyszko J; Malyszko JS; Mysliwiec M
Kidney Blood Press Res; 2009; 32(4):235-8. PubMed ID: 19713706
[TBL] [Abstract][Full Text] [Related]
11. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients.
Costa E; Pereira BJ; Rocha-Pereira P; Rocha S; Reis F; Castro E; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Am J Nephrol; 2008; 28(4):677-83. PubMed ID: 18354252
[TBL] [Abstract][Full Text] [Related]
12. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation.
Xu Y; Ding XQ; Zou JZ; Liu ZH; Jiang SH; Chen YM
J Int Med Res; 2011; 39(5):1961-7. PubMed ID: 22118000
[TBL] [Abstract][Full Text] [Related]
13. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients.
Arabul M; Gullulu M; Yilmaz Y; Eren MA; Baran B; Gul CB; Kocamaz G; Dilek K
Med Sci Monit; 2009 Nov; 15(11):CR583-7. PubMed ID: 19865058
[TBL] [Abstract][Full Text] [Related]
14. DMT1 (NRAMP2/DCT1) genetic variability and resistance to recombinant human erythropoietin therapy in chronic kidney disease patients under haemodialysis.
Costa E; Rocha S; Rocha-Pereira P; Reis F; Castro E; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Acta Haematol; 2008; 120(1):11-3. PubMed ID: 18667808
[No Abstract] [Full Text] [Related]
15. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients.
Reuter SE; Faull RJ; Ranieri E; Evans AM
Nephrol Dial Transplant; 2009 Mar; 24(3):990-6. PubMed ID: 18987259
[TBL] [Abstract][Full Text] [Related]
16. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
[TBL] [Abstract][Full Text] [Related]
17. The anemia of ageing is not associated with increased plasma hepcidin levels.
Lee P; Gelbart T; Waalen J; Beutler E
Blood Cells Mol Dis; 2008; 41(3):252-4. PubMed ID: 18676162
[TBL] [Abstract][Full Text] [Related]
18. An unusual etiology of erythropoietin resistance: hyperthyroidism.
Kaynar K; Ozkan G; Erem C; Gul S; Yilmaz M; Sonmez B; Ozdemir F; Ulusoy S
Ren Fail; 2007; 29(6):759-61. PubMed ID: 17763175
[TBL] [Abstract][Full Text] [Related]
19. European best practice guidelines 14-16: inadequate response to epoetin.
Hörl WH; Jacobs C; Macdougall IC; Valderrábano F; Parrondo I; Thompson K; Carveth BG
Nephrol Dial Transplant; 2000; 15 Suppl 4():43-50. PubMed ID: 11052148
[No Abstract] [Full Text] [Related]
20. IL-6 is an independent risk factor for resistance to erythropoiesis-stimulating agents in hemodialysis patients without iron deficiency.
Won HS; Kim HG; Yun YS; Jeon EK; Ko YH; Kim YS; Kim YO; Yoon SA
Hemodial Int; 2012 Jan; 16(1):31-7. PubMed ID: 22284696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]